Guggenheim maintains buy rating for Johnson & Johnson after FDA approves plaque psoriasis treatment

nl.investing.com (Dutch)

Guggenheim maintained a Buy rating for Johnson & Johnson after the FDA approved its plaque psoriasis treatment, Icotyde. The approval of the oral IL-23 therapy, icotrokinra, came ahead of schedule and is projected to generate over $8 billion in peak annual sales for J&J. Icotyde is being explored for other conditions, and J&J has other promising drug candidates in development, including for bladder cancer.


With a significance score of 2, this news ranks in the top 21% of today's 30026 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: